| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Age-period-cohort effect on lung cancer mortality in Spain, 1982–2021
|
Cayuela, Lucía
|
|
|
178 |
C |
p. 269-276
|
artikel
|
| 2 |
A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis
|
Zhuang, Wei
|
|
|
178 |
C |
p. 131-133
|
artikel
|
| 3 |
Brain imaging in lung cancer staging: A real-world, multi-centre study of prevalence of brain metastases, impact on treatment and re-modelling of the NICE health economic analysis
|
Brockelsby, Christopher
|
|
|
178 |
C |
p. 145-150
|
artikel
|
| 4 |
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib
|
Miao, Emily
|
|
|
178 |
C |
p. 57-65
|
artikel
|
| 5 |
Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial
|
Wang, Na
|
|
|
178 |
C |
p. 183-190
|
artikel
|
| 6 |
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer
|
Langston, Jacob
|
|
|
178 |
C |
p. 103-107
|
artikel
|
| 7 |
Contents
|
|
|
|
178 |
C |
p. v-vii
|
artikel
|
| 8 |
Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal masses
|
Mayoral, Maria
|
|
|
178 |
C |
p. 206-212
|
artikel
|
| 9 |
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer
|
Zeng, Liang
|
|
|
178 |
C |
p. 134-142
|
artikel
|
| 10 |
Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis
|
Furuse, Hideaki
|
|
|
178 |
C |
p. 220-228
|
artikel
|
| 11 |
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer
|
Daher, Sameh
|
|
|
178 |
C |
p. 229-236
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
178 |
C |
p. iii
|
artikel
|
| 13 |
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis
|
Wang, Shuxing
|
|
|
178 |
C |
p. 47-56
|
artikel
|
| 14 |
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas
|
Fan, Junqiang
|
|
|
178 |
C |
p. 123-130
|
artikel
|
| 15 |
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer
|
Akagi, Kazumasa
|
|
|
178 |
C |
p. 247-253
|
artikel
|
| 16 |
Induction and preliminary characterization of neoplastic pulmonary nodules in a transgenic pig model
|
Ghosn, Mario
|
|
|
178 |
C |
p. 157-165
|
artikel
|
| 17 |
KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study
|
Frost, Matilde Grupe
|
|
|
178 |
C |
p. 172-182
|
artikel
|
| 18 |
Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer
|
Visser, Esther
|
|
|
178 |
C |
p. 28-36
|
artikel
|
| 19 |
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
|
Park, Keunchil
|
|
|
178 |
C |
p. 166-171
|
artikel
|
| 20 |
MET alterations in advanced non-small cell lung cancer
|
Sakamoto, Mandy
|
|
|
178 |
C |
p. 254-268
|
artikel
|
| 21 |
Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients
|
Wang, Yuezhu
|
|
|
178 |
C |
p. 37-46
|
artikel
|
| 22 |
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
|
Cheng, Ying
|
|
|
178 |
C |
p. 87-95
|
artikel
|
| 23 |
Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
|
Ollila-Raj, Hely
|
|
|
178 |
C |
p. 213-219
|
artikel
|
| 24 |
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
|
Lv, Chao
|
|
|
178 |
C |
p. 151-156
|
artikel
|
| 25 |
Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy”
|
Furuya, Naoki
|
|
|
178 |
C |
p. 143-144
|
artikel
|
| 26 |
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer
|
Nakasuka, Takamasa
|
|
|
178 |
C |
p. 1-10
|
artikel
|
| 27 |
Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer
|
Zhang, Jiexia
|
|
|
178 |
C |
p. 11-19
|
artikel
|
| 28 |
Proliferative ability of circulating tumor cells is a prognostic factor in Early-Stage lung adenocarcinoma
|
Che, Ting-Fang
|
|
|
178 |
C |
p. 198-205
|
artikel
|
| 29 |
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer
|
Kang, Jin
|
|
|
178 |
C |
p. 66-74
|
artikel
|
| 30 |
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
|
Vergnenegre, Alain
|
|
|
178 |
C |
p. 191-197
|
artikel
|
| 31 |
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial
|
Kievit, H.
|
|
|
178 |
C |
p. 96-102
|
artikel
|
| 32 |
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
|
Auclin, Edouard
|
|
|
178 |
C |
p. 116-122
|
artikel
|
| 33 |
Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection – A systematic review
|
Brandão, Mariana
|
|
|
178 |
C |
p. 75-86
|
artikel
|
| 34 |
The impact of impaired tissue fixation in resected non-small-cell lung cancer on protein deterioration and DNA degradation
|
Butter, Rogier
|
|
|
178 |
C |
p. 108-115
|
artikel
|
| 35 |
TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
|
Hegedüs, Luca
|
|
|
178 |
C |
p. 237-246
|
artikel
|
| 36 |
Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
|
Zhuang, Fenghui
|
|
|
178 |
C |
p. 20-27
|
artikel
|
Tijdschrift beschrijving